Plain-English translation of NCT06229210 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Schizophrenia research guide โPhase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it is safe and well-tolerated in children and teenagers with schizophrenia, bipolar disorder, or autism spectrum disorder. Researchers will monitor how young patients respond to taking this medication once a day over a 26-week period. The goal is to understand whether the medication is suitable for treating these conditions in young people.
While this medication has been studied in adults, doctors need to learn whether it is safe and effective specifically for children and teenagers with these serious conditions. This trial will help determine how young bodies handle the medication and whether it causes any concerning side effects in this age group.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join, you'll have a screening visit (up to 2 weeks) where doctors will check if you qualify. Then you'll enter a 26-week period where you take the medication once daily and visit the clinic regularly so the research team can monitor your health and safety. After your last dose, you'll return for a follow-up visit about 2 weeks later to make sure everything is okay. The entire commitment is roughly 28โ30 weeks.
AI-generated summary from trial data ยท Jul 14, 2026 ยท Not medical advice
United States